WestEnd Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.97K Hold
31
– – ﹤0.01% 130
2026
Q2
$2.17K Buy
31
+4
+15% +$207 ﹤0.01% 181
2026
Q1
$1.37K Hold
27
– – ﹤0.01% 193
2025
Q4
$796 Buy
27
+15
+125% +$408 ﹤0.01% 266
2025
Q3
$310 Sell
12
-2
-14% -$56 ﹤0.01% 354
2025
Q2
$386 Buy
14
+1
+8% +$26 ﹤0.01% 303
2025
Q1
$369 Buy
13
+9
+225% +$319 ﹤0.01% 297
2024
Q4
$166 Hold
4
– – ﹤0.01% 279
2024
Q3
$267 Hold
4
– – ﹤0.01% 258
2024
Q2
$475 Sell
4
-1
-20% -$127 ﹤0.01% 165
2024
Q1
$533 Hold
5
– – ﹤0.01% 149
2023
Q4
$497 Hold
5
– – ﹤0.01% 160
2023
Q3
$516 Buy
+5
New +$558 ﹤0.01% 150
2023
Q1
– Sell
-4
Closed -$660 – 138
2022
Q4
$718 Hold
4
– – ﹤0.01% 122
2022
Q3
$0 Hold
4
– – ﹤0.01% 267
2022
Q2
$571 Buy
+4
New +$572 ﹤0.01% 131
2022
Q1
– Sell
-3
Closed -$505 – 148
2021
Q4
$761 Buy
+3
New +$877 ﹤0.01% 123
2021
Q3
– Hold
0
– – – 93

Other funds holding MRNA

WestEnd Advisors's MRNA Position: Q3 2026 in Review

WestEnd Advisors held its Moderna (MRNA) position steady in Q3 2026 at 31 shares worth $5.97K. The position accounts for ﹤0.01% of the portfolio, ranked #130.

WestEnd Advisors first reported a position in MRNA in Q4 2021 and has held it in 17 quarters since. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • WestEnd Advisors held 31 shares of Moderna worth $5.97K as of Q3 2026.
  • WestEnd Advisors left its Moderna share count unchanged in Q3 2026.
  • Moderna made up ﹤0.01% of WestEnd Advisors's portfolio in Q3 2026, its #130 holding.
  • WestEnd Advisors first reported a position in Moderna in Q4 2021 and has held it in 17 quarters since.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on WestEnd Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.